Guggenheim Lifts Johnson & Johnson (JNJ) Outlook After Solid Q4 and 2026 Guide

Johnson & Johnson (NYSE:JNJ) is included among the 12 Most Profitable Dividend Stocks to Buy successful 2026.

On January 23, Guggenheim expert Vamil Divan raised his terms people connected Johnson & Johnson (NYSE:JNJ) to $240 from $227. The steadfast reiterated a Buy rating. The determination followed what helium described arsenic “solid” fourth-quarter results, on with archetypal 2026 guidance that came successful somewhat up of sell-side expectations.

After the quarter, Divan said helium made respective tweaks to his model. Those included lifting near-term forecasts for Tremfya, factoring successful faster erosion for Stelara, and raising estimates for a fig of newer products. Even with those adjustments, Johnson & Johnson remains a Top Pick successful the large-cap biopharma abstraction successful his view.

The institution reported its fourth-quarter 2025 net connected January 21 and paired the merchandise with a 2026 outlook that landed supra Wall Street’s expectations. What stood retired was that the guidance held up contempt a fewer meaningful headwinds. Among them are a caller cause pricing statement with the Trump medication and astir $500 cardinal successful tariff-related costs tied to the aesculapian devices business.

Johnson & Johnson said the pricing woody reached earlier this month, which is intended to little costs for definite medicine drugs, could extremity up costing the institution “hundreds of millions of dollars.”

Even with that unit baked in, absorption is forecasting 2026 income betwixt $99.5 cardinal and $100.5 billion. That compares with expert expectations of astir $98.9 billion, according to LSEG. On earnings, the institution expects full-year nett of $11.43 to $11.63 per share, somewhat up of the Street’s $11.45 estimate.

Johnson & Johnson (NYSE:JNJ) operates crossed healthcare done its Innovative Medicine and MedTech segments, spanning cause development, aesculapian devices, and a wide portfolio of products sold globally.

While we admit the imaginable of JNJ arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: Dividend Contenders List: Top 20 Stocks and 15 Best High Yield Stocks To Buy.

Disclosure: None.